Abstract
Early recognition is indispensable for the optimal management of Acute Coronary Syndrome (ACS); moreover, early prognostic stratification of patients with established ACS is useful to improve strategies for these patients. The paper focuses attention on troponins (I and T), the most validated biomarker for early diagnosis of ACS and on B-type natriuretic peptide (BNP) and N-terminal proB-type natriuretic peptide (NT-proBNP), the most powerful cardiac marker after troponin to be used as prognostic indicator in patients with ACS. We pay particular attention to the troponin story in ACS, including discussions about high sensitivity methods and on the most recent techniques (e.g. Point Of Care) available to shorten times from the blood sampling to the validated report [Turn around time (TAT) arm-to-report]. We report the differences between BNP and NT-proBNP, both from an analytical and a clinical point of view and discuss the use of cardiac natriuretic peptides for early recognition of cardiac insufficiency and early management of patients presenting to Emergency Departments with dyspnoea. Finally, we briefly discuss the most promising new cardiac markers actually used only in preclinical studies.
Keywords: Acute coronary syndromes, troponin, natriuretic peptide, point of care, cardiac markers
Current Vascular Pharmacology
Title: Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Volume: 8 Issue: 3
Author(s): Gianfranco Amodio, Gianfranco Antonelli and Francesca Di Serio
Affiliation:
Keywords: Acute coronary syndromes, troponin, natriuretic peptide, point of care, cardiac markers
Abstract: Early recognition is indispensable for the optimal management of Acute Coronary Syndrome (ACS); moreover, early prognostic stratification of patients with established ACS is useful to improve strategies for these patients. The paper focuses attention on troponins (I and T), the most validated biomarker for early diagnosis of ACS and on B-type natriuretic peptide (BNP) and N-terminal proB-type natriuretic peptide (NT-proBNP), the most powerful cardiac marker after troponin to be used as prognostic indicator in patients with ACS. We pay particular attention to the troponin story in ACS, including discussions about high sensitivity methods and on the most recent techniques (e.g. Point Of Care) available to shorten times from the blood sampling to the validated report [Turn around time (TAT) arm-to-report]. We report the differences between BNP and NT-proBNP, both from an analytical and a clinical point of view and discuss the use of cardiac natriuretic peptides for early recognition of cardiac insufficiency and early management of patients presenting to Emergency Departments with dyspnoea. Finally, we briefly discuss the most promising new cardiac markers actually used only in preclinical studies.
Export Options
About this article
Cite this article as:
Amodio Gianfranco, Antonelli Gianfranco and Di Serio Francesca, Cardiac Biomarkers in Acute Coronary Syndromes: A Review, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112250
DOI https://dx.doi.org/10.2174/157016110791112250 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mediterranean and other Dietary Patterns in Secondary Cardiovascular Disease Prevention: A Review
Current Vascular Pharmacology The Epidemiology of Adiposity and Dementia
Current Alzheimer Research Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology Pindolol Augmentation of Antidepressant Response
Current Drug Targets Further Issues with New Oral Anticoagulants
Current Pharmaceutical Design The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Statin Drugs, Metabolic Pathways, and Asthma: A Therapeutic Opportunity Needing Further Research
Drug Metabolism Letters Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment
Current Pharmaceutical Design The Effects of Creatine Supplementation and Physical Exercise on Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the “Low-Risk” Patients?
Current Drug Targets The Role of Platelets in Bone Remodeling
Inflammation & Allergy - Drug Targets (Discontinued) [General Articles] Intracellular Thiol Concentration Modulating Inflammatory Response: Influence on the Regulation of Cell Functions Through Cysteine Prodrug Approach
Current Medicinal Chemistry Obesity and Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Therapeutic Targets for Metabolic Syndrome: Lessons from Animal Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Lyn Regulates Cytotoxicity in Respiratory Epithelial Cells Challenged by Cigarette Smoke Extracts
Current Molecular Medicine